In focus · trending topic

clinicaltrial

50 stories · following the connections

Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa

By Nasdaq OMXJul 18, 2017, 12:05 PM UTC

Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program

By Nasdaq OMXJun 29, 2017, 12:15 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 30, 2017, 12:32 PM UTC